Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine vs standard bupivacaine for adductor canal block in total knee arthroplasty
ChiCTR2400084532Phase 4Not yet recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- May 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of liposomal bupivacaine in knee osteoarthritis (OA) (2 arms), sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoint: VAS score (resting and movement). Planned start May 2024; status: not yet recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2400084532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084532.